

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



CAY10726

Item No. 23859

CAS Registry No.: 1611446-66-2

Formal Name: 16-[[[4-chloro-3-(trifluoromethyl)

phenyllaminolcarbonyllaminol-

hexadecanoic acid

MF: $C_{24}H_{36}CIF_3N_2O_3$

493.0 FW: **Purity:** ≥98% UV/Vis.: λ_{max} : 253 nm A crystalline solid Supplied as:

Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

COOH

Laboratory Procedures

CAY10726 is supplied as a crystalline solid. A stock solution may be made by dissolving the CAY10726 in the solvent of choice. CAY10726 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CAY10726 in these solvents is approximately 12, 5, and 20 mg/ml, respectively.

CAY10726 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CAY10726 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CAY10726 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CAY10726 is an arylurea fatty acid.¹ It decreases ATP production by 28% in MDA-MB-231 breast cancer cells when used at a concentration of 10 µM. CAY10726 decreases proliferation and initiates apoptosis in MDA-MB-231 cells via depletion of the phospholipid cardiolipin and its precursor phosphatidylglycerol from the mitochondrial membrane. In vivo, CAY10726 (2.5-40 mg/kg) reduces tumor volume and increases tumor cell apoptosis in a mouse MDA-MB-231 breast cancer xenograft model in a dose-dependent manner.

Reference

1. Rawling, T., Choucair, H., Koolaji, N., et al. A novel arylurea fatty acid that targets the mitochondrion and depletes cardiolipin to promote killing of breast cancer cells. J. Med. Chem. 60(20), 8661-8666 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 01/29/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM